These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control. Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y Front Immunol; 2018; 9():1266. PubMed ID: 29928278 [TBL] [Abstract][Full Text] [Related]
25. Dendritic cells combined with tumor cells and α-galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. Escribà-Garcia L; Alvarez-Fernández C; Tellez-Gabriel M; Sierra J; Briones J J Transl Med; 2017 May; 15(1):115. PubMed ID: 28549432 [TBL] [Abstract][Full Text] [Related]
26. Understanding the behavior of invariant NKT cells in autoimmune diseases. Yamamura T; Sakuishi K; Illés Z; Miyake S J Neuroimmunol; 2007 Nov; 191(1-2):8-15. PubMed ID: 17905445 [TBL] [Abstract][Full Text] [Related]
27. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Van Kaer L; Parekh VV; Wu L Immunotherapy; 2011 Jan; 3(1):59-75. PubMed ID: 21174558 [TBL] [Abstract][Full Text] [Related]
28. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR. Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390 [TBL] [Abstract][Full Text] [Related]
29. α-Lactosylceramide Protects Against iNKT-Mediated Murine Airway Hyperreactivity and Liver Injury Through Competitive Inhibition of Cd1d Binding. Lai AC; Chi PY; Thio CL; Han YC; Kao HN; Hsieh HW; Gervay-Hague J; Chang YJ Front Chem; 2019; 7():811. PubMed ID: 31850305 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseases. Miyake S; Yamamura T Int Rev Immunol; 2007; 26(1-2):73-94. PubMed ID: 17454265 [TBL] [Abstract][Full Text] [Related]
31. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Fujii S; Shimizu K; Hemmi H; Fukui M; Bonito AJ; Chen G; Franck RW; Tsuji M; Steinman RM Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11252-7. PubMed ID: 16844772 [TBL] [Abstract][Full Text] [Related]
32. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913 [TBL] [Abstract][Full Text] [Related]
33. Alpha-lactosylceramide as a novel "sugar-capped" CD1d ligand for natural killer T cells: biased cytokine profile and therapeutic activities. Zhang W; Zheng X; Xia C; Perali RS; Yao Q; Liu Y; Zheng P; Wang PG Chembiochem; 2008 Jun; 9(9):1423-30. PubMed ID: 18478523 [TBL] [Abstract][Full Text] [Related]
34. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Miyamoto K; Miyake S; Yamamura T Nature; 2001 Oct; 413(6855):531-4. PubMed ID: 11586362 [TBL] [Abstract][Full Text] [Related]
35. Roles of NKT cells in cancer immunotherapy. Bae EA; Seo H; Kim IK; Jeon I; Kang CY Arch Pharm Res; 2019 Jul; 42(7):543-548. PubMed ID: 30859410 [TBL] [Abstract][Full Text] [Related]
36. α-GalCer and iNKT Cell-Based Cancer Immunotherapy: Realizing the Therapeutic Potentials. Zhang Y; Springfield R; Chen S; Li X; Feng X; Moshirian R; Yang R; Yuan W Front Immunol; 2019; 10():1126. PubMed ID: 31244823 [TBL] [Abstract][Full Text] [Related]
37. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide. Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160 [TBL] [Abstract][Full Text] [Related]
38. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Song W; van der Vliet HJ; Tai YT; Prabhala R; Wang R; Podar K; Catley L; Shammas MA; Anderson KC; Balk SP; Exley MA; Munshi NC Clin Cancer Res; 2008 Nov; 14(21):6955-62. PubMed ID: 18980990 [TBL] [Abstract][Full Text] [Related]
39. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α. Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798 [TBL] [Abstract][Full Text] [Related]
40. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer. Takami M; Ihara F; Motohashi S Front Immunol; 2018; 9():2021. PubMed ID: 30245690 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]